| 前收盘价格 | 34.55 |
| 收盘价格 | 34.95 |
| 成交量 | 411,078 |
| 平均成交量 (3个月) | 619,377 |
| 市值 | 1,444,513,280 |
| 预期市盈率 (P/E Forward) | 100.00 |
| 价格/销量 (P/S) | 10.42 |
| 股市价格/股市净资产 (P/B) | 5.15 |
| 52周波幅 | |
| 利润日期 | 7 Nov 2024 |
| 营业毛利率 | -23.92% |
| 营业利益率 (TTM) | -26.13% |
| 稀释每股收益 (EPS TTM) | -0.810 |
| 季度收入增长率 (YOY) | 59.10% |
| 总债务/股东权益 (D/E MRQ) | 4.08% |
| 流动比率 (MRQ) | 12.67 |
| 营业现金流 (OCF TTM) | -20.99 M |
| 杠杆自由现金流 (LFCF TTM) | -13.30 M |
| 资产报酬率 (ROA TTM) | -9.92% |
| 股东权益报酬率 (ROE TTM) | -13.99% |
市场趋势
| 短期 | 中期 | ||
| 行业 | Medical Devices (US) | 混合的 | 混合的 |
| Medical Devices (全球的) | 混合的 | 混合的 | |
| 股票 | RxSight, Inc. | 看跌 | 看涨 |
AIStockmoo 评分
2.1
| 分析师共识 | 1.0 |
| 内部交易活动 | NA |
| 价格波动 | 5.0 |
| 技术平均移动指标 | 5.0 |
| 技术振荡指标 | -2.5 |
| 平均 | 2.13 |
|
RxSight Inc is a commercial-stage medical technology company dedicated towards improving the vision of patients following cataract surgery. It offers intraocular lens technology that enables doctors to customize and optimize visual acuity for patients after cataract surgery. The Company operates and manages its business in one reportable segment, the research and development, manufacture and sale of light adjustable lenses and related capital equipment. |
|
| 部门 | Healthcare |
| 行业 | Medical Devices |
| 投资方式 | Small Growth |
| 内部持股比例 | 5.08% |
| 机构持股比例 | 89.47% |
所有权
| 姓名 | 日期 | 持有股份 |
|---|---|---|
| Summit Partners Public Asset Management, Llc | 30 Sep 2024 | 687,711 |
| 52周波幅 | ||
| 目标价格波幅 | ||
| 高 | 72.00 (Jefferies, 100.89%) | 购买 |
| 中 | 47.00 (31.14%) | |
| 低 | 40.00 (Stifel, 11.61%) | 保留 |
| 平均值 | 51.50 (43.69%) | |
| 总计 | 2 购买, 2 保留 | |
| 平均价格@调整类型 | 41.64 | |
| 公司 | 日期 | 目标价格 | 调整类型 | 价格@调整类型 |
|---|---|---|---|---|
| Stifel | 20 Dec 2024 | 40.00 (11.61%) | 保留 | 33.66 |
| Wells Fargo | 11 Dec 2024 | 42.00 (17.19%) | 保留 | 37.58 |
| UBS | 06 Dec 2024 | 52.00 (45.09%) | 购买 | 43.15 |
| Jefferies | 29 Oct 2024 | 72.00 (100.89%) | 购买 | 52.16 |
该时间范围内无数据。
| 日期 | 类型 | 细节 |
|---|---|---|
| 02 Jan 2025 | 公告 | RxSight, Inc. to Present at the J.P. Morgan Healthcare Conference |
| 07 Nov 2024 | 公告 | RxSight, Inc. Reports Third Quarter 2024 Financial Results |
| 24 Oct 2024 | 公告 | RxSight, Inc. to Report Third Quarter Financial Results on November 7, 2024 |
支撑、阻力和趋势线水平是由人工智能（AI）模型生成的，请谨慎解读。
投资组合